Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
Holding TBPH?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.17Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: -3.70%
|Next Earnings Date:Aug 01, 2018
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for Theravance Biopharma with strong sales growth in key products like YUPELRI and TRELEGY, alongside effective cost management and strategic initiatives aimed at maximizing shareholder value. However, the presence of a noncash impairment charge and extended timelines for the CYPRESS study were noted challenges.Company Guidance
During the Theravance Biopharma Q3 2024 earnings call, several key metrics and strategic updates were discussed. YUPELRI achieved a record quarterly net sales of $62.2 million, marking a 7% year-over-year growth and 14% quarter-on-quarter increase, driven by a 14% rise in demand and a 40% boost in hospital doses compared to the previous year. The TRELEGY product also performed well, with sales reaching $789 million for the quarter, contributing to year-to-date sales of $2.6 billion, up 30%. The company is on track to achieve a $50 million sales milestone contingent on Q4 sales exceeding $610 million, significantly below consensus estimates. Additionally, Theravance is progressing with its CYPRESS study for ampreloxetine, expecting to enroll the final patient by mid-2025, with top-line results anticipated six months later. Financially, the company reported collaboration revenue of $16.9 million, an 8% increase from the previous year, and maintained a strong cash position of $91 million with 49 million shares outstanding. The board has also initiated a Strategic Review Committee to explore ways to enhance shareholder value, highlighting the company's focus on strategic growth and capital efficiency.YUPELRI Sales Growth
YUPELRI achieved a record high in quarterly net sales, reaching $62.2 million, with 7% year-over-year growth and 14% quarter-on-quarter growth. Hospital doses increased 40% year-over-year.
TRELEGY Sales and Milestones
GSK's TRELEGY sales increased 17% to $789 million in Q3, with year-to-date sales up 30% to $2.6 billion. Theravance is positioned to achieve a $50 million sales milestone in 2024, with potential for $150 million in additional milestones in 2025 and 2026.
Financial Performance
Theravance reported $16.9 million in collaboration revenue, marking an 8% increase from last year. G&A expenses decreased by 21% year-to-date, and share-based compensation was reduced by 21% compared to last year.
Strategic Initiatives
Theravance formed a Strategic Review Committee to explore alternatives for unlocking company value, with Lazard acting as a financial advisor.
---
TBPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TBPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $8.91 | $9.68 | +8.64% |
| Aug 05, 2024 | $9.59 | $7.83 | -18.35% |
| May 13, 2024 | $9.58 | $9.39 | -1.98% |
| Feb 26, 2024 | $9.23 | $9.69 | +4.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Theravance Biopharma (TBPH) report earnings?
Theravance Biopharma (TBPH) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Theravance Biopharma (TBPH) earnings time?
Theravance Biopharma (TBPH) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TBPH EPS forecast?
TBPH EPS forecast for the fiscal quarter 2024 (Q4) is -0.2.
---